1.Clinical Observation of Jiuxin Fumai Injection for Treatment of Syncope-Collapse Syndrome
Can LI ; Daosheng HUANG ; Jiangang YANG ; Weiguang ZHU ; Mingda HE
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(01):-
0.05);the therapeutic effect on slight syncope-collapse syndrome and septic shock is superior to the control group(P
2.Long-term Toxicity of Jiuxin Fumai Injection in Rats
Can LI ; Daosheng HUANG ; Bingwu ZHONG ; Jiangang YANG ; Zhaoquan SUN ; Liyi LIU
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(04):-
Objective To observe the long-term toxicity of Jiuxin Fumai Injection and to investigate the safety of clinical medication.Methods The rats were given intramuscular injection with Jiuxin Fumai Injection in large,medium,small dosage(respectively 20,10,5g? kg-1)every day for two weeks,and normal saline group served as the normal control.Two weeks after drug withdrawal,the toxic reaction in rats was observed.Results After two-week continuous administration,all the animals were alive.Some animals were vomiting and getting excited when administered the large dosage and medium dosage injection.The blood sugar elevated,the thoracic gland coefficient lowered,the hepatic cells were cloudily swollen in the animals of large dosage group.Two weeks after drug withdrawal,the above phenomenon vanished.There was no obvious toxic reaction in the small-dosage injection group.Conclusion Long-term administration of Jiuxin Fumai Injection in large dosage shows certain toxic reaction in rats.The safe dosage for intramuscular administration is less than 5 g? kg-1? d-1.
3.Investigation of ABO allelic competition phenomena in a pedigree with Bw11 subtype.
Chenchen FENG ; Weichao REN ; Daosheng CHENG ; Jingyan GAO ; Jianyong CHEN ; Weichao LI ; Jianyu XIAO ; Taixiang LIU ; Chengyin HUANG ; Qing CHEN
Chinese Journal of Medical Genetics 2021;38(1):23-26
OBJECTIVE:
To investigate the serological and molecular characteristics of a pedigree carrying an allele for ABO*BW.11 blood subgroup.
METHODS:
The ABO blood type of 9 pedigree members were determined by serological methods. Exons 6 and 7 of the ABO gene were amplified by PCR and directly sequenced. The patient and her father were also subjected to clone sequencing analysis.
RESULTS:
Serological tests demonstrated that the proband and her younger brother had an ABw subtype, whilst her father and two daughters had Bw subtype. Clone sequencing found that the exon 7 of the ABO gene of the proband had a T>C substitution at position 695, which was identified as a BW.11 allele compared with the reference sequence B.01. This BW.11 allele was also identified in the proband's father, brother and two daughters. Due to allelic competition, the A/BW.11 and BW.11/O alleles demonstrated significantly different phenotypes.
CONCLUSION
The c.695T>C substitution of the ABO gene may lead to allelic competition in the Bw11 subtype. Combined molecular and serological methods is helpful for precise blood grouping.
ABO Blood-Group System/genetics*
;
Alleles
;
Female
;
Genotype
;
Humans
;
Male
;
Pedigree
;
Phenotype
4.Professor LIU Minru's Medication Rule in Treatment of Polycystic Ovary Syndrome (Intracellular Lipid Membrane Congestion Syndrome)
Xinbo HE ; Xiang HU ; Minru LIU ; Fuzhu LI ; Yuhuan HUANG
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(20):169-176
ObjectiveTo analyze and sum up the medication rule and the core prescription of Professor LIU Minru in the treatment of polycystic ovary syndrome (intracellular lipid membrane congestion syndrome)and explore the effect mechanism underlying the medication. MethodTwo platforms were used to carry out data mining to analyze the characteristics and rules of Professor LIU's prescriptions for the treatment of this disease. Network pharmacology was used to further clarify active ingredients in the core prescription,and a traditional Chinese medicine-active ingredient-target network was constructed,with the potential mechanism of action analyzed. ResultA total of 321 prescriptions were included in the medical records,involving 178 Chinese medicinals and 28 kinds of formula granules.The Chinese medicinals mainly act on the liver and kidney meridians, whose main tastes were sweetness,pungency,and bitterness and properties were mainly warm,mild,and slightly cold.Commonly used medicine pairs include Dioscoreae Rhizoma-Rehmanniae Radix Praeparata,Chuanxiong Rhizoma-Angelicae Sinensis Radix,Bupleuri Radix-Aurantii Fructus,and Gleditsiae Spina-Curcumae Rhizoma.The commonly used formulas are Xuefu Zhuyutang,Siwugang,Yangjing Zhongyutang,etc. The core prescription is composed of 12 Chinese medicinals such as angelica,white peony,saponaria thorn,and epimedium,containing 74 active ingredients,including quercetin,luteolin,kaempferol,fisetin,and β-sitosterol.A total of 37 key targets were found,involving phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt),mitogen-activated protein kinase (MAPK),Janus protein tyrosine kinase (JAK)/signal transduction and activator of transcription (STAT),and other signaling pathways. ConclusionThe pathogenesis of this disease is complex.Professor LIU adheres to the pathogenesis of "kidney deficiency as the root cause,and phlegm retention as the symptom". Under the guidance of the academic ideology of "kidney Qi as the root,and protecting Yin as the foundation" and "nurturing Yin to support Yang",she takes into account Yin and Yang in kidney tonic,replenishes and consolidates the essence and blood,and relieves manifestations by dissipating mass, activating blood, and regulating Qi. She has a rigorous thinking in formulating prescriptions. The core prescription has the characteristics of comprehensive regulation by multiple components at multiple targets in multiple pathways.